B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Cumberland Pharmaceuticals (CPIX) today and set a price target of $9.00. The company’s shares closed last Monday at $4.75, close to its 52-week low of $4.70.
According to TipRanks.com, D’silva ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.1% and a 31.9% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Eton Pharmaceuticals, and Sensus Healthcare.
Currently, the analyst consensus on Cumberland Pharmaceuticals is a Moderate Buy with an average price target of $9.00.
See today’s analyst top recommended stocks >>
Based on Cumberland Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $1.95 million. In comparison, last year the company had a GAAP net loss of $1.64 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cumberland Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Hepatoren, Vaprisol, Boxaban, Vasculan, Ethyol, Portaban, and Totect.